학술논문
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
Document Type
Article
Author
Source
In Annals of Oncology February 2020 31(2):228-235
Subject
Language
ISSN
0923-7534